Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Your Environment. Your Health.

Publication Detail

Title: m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade.

Authors: Yang, Seungwon; Wei, Jiangbo; Cui, Yan-Hong; Park, Gayoung; Shah, Palak; Deng, Yu; Aplin, Andrew E; Lu, Zhike; Hwang, Seungmin; He, Chuan; He, Yu-Ying

Published In Nat Commun, (2019 06 25)

Abstract: Melanoma is one of the most deadly and therapy-resistant cancers. Here we show that N6-methyladenosine (m6A) mRNA demethylation by fat mass and obesity-associated protein (FTO) increases melanoma growth and decreases response to anti-PD-1 blockade immunotherapy. FTO level is increased in human melanoma and enhances melanoma tumorigenesis in mice. FTO is induced by metabolic starvation stress through the autophagy and NF-κB pathway. Knockdown of FTO increases m6A methylation in the critical protumorigenic melanoma cell-intrinsic genes including PD-1 (PDCD1), CXCR4, and SOX10, leading to increased RNA decay through the m6A reader YTHDF2. Knockdown of FTO sensitizes melanoma cells to interferon gamma (IFNγ) and sensitizes melanoma to anti-PD-1 treatment in mice, depending on adaptive immunity. Our findings demonstrate a crucial role of FTO as an m6A demethylase in promoting melanoma tumorigenesis and anti-PD-1 resistance, and suggest that the combination of FTO inhibition with anti-PD-1 blockade may reduce the resistance to immunotherapy in melanoma.

PubMed ID: 31239444 Exiting the NIEHS site

MeSH Terms: Adenosine/analogs & derivatives*; Adenosine/genetics; Adenosine/metabolism; Alpha-Ketoglutarate-Dependent Dioxygenase FTO/genetics; Alpha-Ketoglutarate-Dependent Dioxygenase FTO/metabolism*; Animals; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal/administration & dosage*; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; DNA Methylation; Demethylation; Female; Humans; Immunotherapy; Melanoma/enzymology*; Melanoma/genetics; Melanoma/pathology; Melanoma/therapy*; Mice; Mice, Inbred C57BL; Mice, Nude; Programmed Cell Death 1 Receptor/genetics; Programmed Cell Death 1 Receptor/immunology; RNA Stability; RNA, Messenger/genetics; RNA, Messenger/metabolism

to Top